Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22796541 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL29518078 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL22796538 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL29558966 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL1812906 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL29416301 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL31084946 | 1.00 | CALCRL (0.38) | CALCRLALOX15HTTNPC1ALDH1A1 | |
| SCHEMBL1812252 | 0.91 | CALCRL (0.38) | CALCRLNPC1BACE1RAMP1 | |
| SCHEMBL28717222 | 0.91 | CALCRL (0.38) | CALCRLNPC1BACE1RAMP1 | |
| SCHEMBL16912987 | 0.90 | CALCRL (0.35) | CALCRLNPC1RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-3983417-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CALCRL 1/4885ALOX15 953/4885HTT 3040/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CALCRL 1/4885ALOX15 953/4885HTT 3040/4885 |
| US-20220306651-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, CALCA | CALCRL 1/4885ALOX15 1594/4885HTT 2676/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | CALCRL 1/4885ALOX15 953/4885HTT 3040/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885ALOX15 1614/4885HTT 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.